This CPB has been updated, for Medicare Advantage plans that do not offer prescription drug coverage (MA), to designate Remicade or Renflexis as the preferred brand for Crohn's disease and plaque psoriasis. This CPB has been updated, for Medicare Advantage plans that offer prescription drug coverage (MAPD), to designate Humira as the preferred brand for Crohn's disease. This CPB has been updated, for Medicare Advantage plans that do not offer prescription drug coverage (MA) and Medicare Advantage plans that offer prescription drug coverage (MAPD), to designate Remicade or Renflexis as the preferred brand for ulcerative colitis.